Sanofi and Regeneron Present More Positive Data for Dupixent Product

Health News

PARIS (Reuters) – Healthcare companies Sanofi and partner Regeneron presented on Tuesday more positive data for their Dupixent product.

The companies said new data showed that Dupixent showed a significant histological remission of eosinophilic esophagitis in children 1 to 11 years old. Eosinophilic esophagitis is a chronic inflammatory disease that damages the esophagus and prevents it from working properly.

(Reporting by Sudip Kar-Gupta; Editing by Christian Schmollinger)

Source: Read Full Article

Related posts:

First-degree burn: Definition, symptoms, and treatments Certain spots on the finger signs for the diseases of nails are often As virus flares globally, new strategies target hot spots How psychotherapy can be provided in times of COVID-19 The huge and growing primary care needs of people with diabetes who have survived COVID-19